Itraconazole - perspectives for the management of invasive aspergillosis

被引:14
作者
Groll, AH
机构
[1] Univ Munster, Med Ctr, Ctr Bone Marrow Transplantat, Infect Dis Res Program, D-48129 Munster, Germany
[2] Univ Munster, Med Ctr, Dept Pediat, Div Pediat Hematol Oncol, D-4400 Munster, Germany
关键词
mycoses; aspergillosis; treatment; antifungal agents; itraconazole;
D O I
10.1111/j.1439-0507.2002.tb04770.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Itraconazole has become an important option in the management of invasive aspergillosis. The compound has potent and broad spectrum antifungal activity in vitro against Aspergillus spp. with a species- and strain dependent fungicidal mode of action. In vivo, the antifungal efficacy of itraconazole has been demonstrated in several non-immunocompromised and immunocompromised animal models of disseminated and invasive pulmonary aspergillosis. Itraconazole is available in oral and intravenous formulations, displays non-linear plasma pharmacokinetics, and is usually well tolerated. Non-comparative clinical data of itraconazole for therapy of suspected or proven invasive aspergillosis suggest response rates similar to those of conventional amphotericin B; however, the experience with itraconazole for induction therapy of invasive aspergillosis is limited, particularly in profoundly neutropenic patients. Itraconazole has an important role for consolidation and maintenance therapy of patients with invasive aspergillosis, and novel combination therapies involving itraconazole are currently under intensive preclinical investigation as to their usefulness for primary therapy.
引用
收藏
页码:48 / 55
页数:8
相关论文
共 61 条
  • [11] DEBEULE K, 1988, MYCOSES, V31, P476, DOI 10.1111/j.1439-0507.1988.tb03653.x
  • [12] TREATMENT OF INVASIVE ASPERGILLOSIS WITH ITRACONAZOLE
    DENNING, DW
    TUCKER, RM
    HANSON, LH
    STEVENS, DA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1989, 86 (06) : 791 - 800
  • [13] Itraconazole resistance in Aspergillus fumigatus
    Denning, DW
    Venkateswarlu, K
    Oakley, KL
    Anderson, MJ
    Manning, NJ
    Stevens, DA
    Warnock, DW
    Kelly, SL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) : 1364 - 1368
  • [14] Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
    Denning, DW
    Radford, SA
    Oakley, KL
    Hall, L
    Johnson, EM
    Warnock, DW
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) : 401 - 414
  • [15] NIAID MYCOSES STUDY-GROUP MULTICENTER TRIAL OF ORAL ITRACONAZOLE THERAPY FOR INVASIVE ASPERGILLOSIS
    DENNING, DW
    LEE, JY
    HOSTETLER, JS
    PAPPAS, P
    KAUFFMAN, CA
    DEWSNUP, DH
    GALGIANI, JN
    GRAYBILL, JR
    SUGAR, AM
    CATANZARO, A
    GALLIS, H
    PERFECT, JR
    DOCKERY, B
    DISMUKES, WE
    STEVENS, DA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02) : 135 - 144
  • [16] An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome
    Denning, DW
    Marinus, A
    Cohen, J
    Spence, D
    Herbrecht, R
    Pagano, L
    Kibbler, C
    Kcrmery, V
    Offner, F
    Cordonnier, C
    Jehn, U
    Ellis, M
    Collette, L
    Sylvester, R
    [J]. JOURNAL OF INFECTION, 1998, 37 (02) : 173 - 180
  • [17] Invasive aspergillosis
    Denning, DW
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) : 781 - 803
  • [19] Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi
    Espinel-Ingroff, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (04) : 1360 - 1367
  • [20] Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia
    Glasmacher, A
    Molitor, E
    Hahn, C
    Bomba, K
    Ewig, S
    Leutner, C
    Wardelmann, E
    Schmidt-Wolf, IGH
    Mezger, J
    Marklein, G
    Sauerbruch, T
    [J]. LEUKEMIA, 1998, 12 (09) : 1338 - 1343